abstract: OBJECTIVE: As part of new drug development initiatives in Thailand, a new tablet formulation of @entity5 ( @entity4 , an antimalarial drug) has been developed. Our previous bioequivalence study indicated that the new and reference @entity4 formulations were well tolerated; however, a significant decrease in hemoglobin was detected after a single 200-mg oral dose. To explore further, a clinical study with an emphasis on hematological parameters was conducted. METHODS: A single-center, randomized, single-blind, cross-over clinical study was conducted in 18 healthy volunteers with a dosage of 300 mg daily for 2 days. @entity2 was used as a comparator. Adverse events were monitored and laboratory parameters on study Days 0, 2, 5, and 7 post drug administrations were analyzed. RESULTS: Eighteen volunteers completed both rounds of the study. Both drugs were well tolerated. All adverse events were mild. Significant decrease in hemoglobin compared to baseline was detected for both drugs 7 days after administration ( @entity4 : 0.48 g/dl, p = 0.007; artesunate 0.38 g/dl, p = 0.001). Transient @entity1 was evidenced by reduction of reticulocytes with a lowest number on study Day 5 (artesunate 75% reduction in reticulocyte count; @entity4 47%, p < 0.001 for both drugs compared to baseline). CONCLUSION: The present study confirmed our previous finding on significant decrease in hemoglobin. Artesunate appeared to have more negative effects on the numbers of reticulocytes and white blood cells than @entity4 . Systemic laboratory and @entity0 profiles presented in this study may be used as a framework for future clinical studies of @entity3 and its derivatives.

title: Comparative study of XXXX and @entity2 safety in healthy Thai volunteers.

answer: @entity5


abstract: AIMS: IgA @entity1 ( @entity6 ) is the most frequent @entity3 around the globe, but its incidence in the United States is unknown. The disease has a preponderance for certain racial/ethnic groups. Our goals were to retrospectively analyze a series of @entity6 biopsies from the state of New Mexico and to calculate an estimated incidence. Then we compared the racial/ethnic composition of our @entity0 cohort to the composition of the New Mexico population and examined the three main racial/ethnic groups for differences in clinical and pathologic parameters. MATERIALS AND METHODS: Renal biopsies and clinical data from @entity6 cases newly diagnosed in New Mexico between 2000 and 2005 were reviewed. We compared the racial/ethnic composition of our @entity0 cohort to the demographic composition of the New Mexico population. Demographic, clinical, and histopathologic variables were analyzed with respect to the @entity0 ' race/ethnicity. RESULTS: The incidence of @entity6 in New Mexico was 10.2 cases per million @entity0 per year (9.3 when Henoch-Sch  nlein purpura cases were excluded). American Indians were twice as frequent in our @entity0 cohort when compared to their demographic representation, with the reverse finding for Non-Hispanic Whites. Hispanics more frequently had @entity5 range @entity4 than Non-Hispanic Whites and American Indians. On renal biopsy, endocapillary proliferative @entity3 was the most common @entity1 , followed by the @entity2 ( @entity2 )-like pattern. The @entity2 -like pattern was more frequent in American Indians and Hispanics than in Non-Hispanic Whites. CONCLUSIONS: This is the first report of an incidence figure of @entity6 for an entire state in the US. American Indian and Hispanic @entity0 had a stronger representation in our cohort than Non-Hispanic Whites, when compared to the general New Mexico population.

title: IgA XXXX in the triethnic population of New Mexico.

answer: @entity1


abstract: To evaluate the effects of @entity2 ( @entity2 ) on bone mass and structure, we have studied the iliac crest biopsies of 27 @entity0 , 10 males (28-68 yr old) and 17 females (26-72 yr old) with mild @entity2 after in vivo @entity3 labeling. All @entity0 had mild @entity4 in the absence of any other cause and elevated levels of PTH without radiological evidence of @entity1 . Static parameters of bone turnover (osteoid surface, osteoid volume, and eroded surface) were elevated in both @entity0 and @entity0 compared to normal values; the midmolecule RIA for PTH (PTHMM) was positively correlated with osteoid surface (r = 0.44; P less than 0.025) and eroded surface (r = 0.58; P less than 0.005). Dynamic parameters of bone turnover (mineralizing surface, expressed as double plus half single labeled surface, and bone formation rate at tissue level) were elevated compared to normal values; PTHMM was positively correlated with double plus half single labeled surfaces (r = 0.33; P less than 0.05) and with bone formation rate at the tissue level (r = 0.37; P less than 0.05). The mineral apposition rate was within the limits of normal values and positively correlated with PTHMM (r = 0.34; P less than 0.05). Histomorphometric parameters of bone structure [cancellous bone volume (BV/TV), trabecular thickness (Tb. Th), trabecular number (Tb.N), trabecular separation (Tb.Sp), cortical thickness (Ct.Th), and total bone density (TBD)] were compared to those in 20 autopsy control subjects, 12 @entity0 (33-60 yr old) and 8 @entity0 (27-75 yr old). BV/TV and Tb.N were significantly higher in @entity2 @entity0 than controls (P less than 0.02 and P less than 0.001, respectively). Tb.Sp was significantly lower in @entity2 @entity0 than controls (P less than 0.001), whereas Tb.Th was not significantly different between @entity2 @entity0 and controls. Ct.Th was significantly lower in @entity2 @entity0 than in controls (P less than 0.001), whereas TBD was not significantly different between the two groups. BV/TV was negatively correlated with age in both controls and @entity2 @entity0 . Tb.N showed a negative correlation and Tb.Sp a positive correlation with age in controls (r = -0.47; P less than 0.05 and r = 0.52; P less than 0.02, respectively), but they were not significantly dependent on age in @entity2 @entity0 . Tb.Th, while showing no significant age-related change in controls, was negatively correlated with age in @entity2 @entity0 (r = -0.42; P less than 0.05).(ABSTRACT TRUNCATED AT 400 WORDS)

title: The histomorphometry of bone in XXXX : preservation of cancellous bone structure.

answer: @entity2


abstract: PURPOSE: To determine indications, therapeutic success, and corneal transplantation techniques for advanced medically uncontrolled @entity4 . DESIGN: Retrospective, interventional case series. METHODS: A review of 92 consecutive @entity0 (1991 to 2002) who underwent therapeutic keratoplasty for @entity5 performed at Singapore National Eye Centre. Causative organism(s) were identified and outcomes were evaluated in terms of infectious cure (therapeutic success), graft clarity, and visual acuity. RESULTS: @entity3 (58.7%) and Fusarium species (32.3%) were the predominant organisms for @entity2 , respectively. Keratoplasty types included penetrating keratoplasty (PK; n = 80) and lamellar keratoplasty (n = 12). Mean graft diameter was 9.5 mm (range, 5.5 to 14 mm). Seventy-four @entity0 (80.4%) achieved therapeutic success after one keratoplasty procedure, three @entity0 were cured after a second keratoplasty. Life-table survival analysis computed the one-year therapeutic survival for @entity2 as 76.6% and 72.4%, respectively (P = .76). The Kaplan-Meier one-year survival rate for PK optical clarity was 72%. Twenty-two @entity0 underwent repeat keratoplasty for various reasons (optical, n = 8; recurrent @entity1 , n = 7; perforation or subsequent new @entity1 , n = 7). Of the 15 @entity0 for whom therapy failed, 11 had @entity2 . Infection recurrence time was four days to one year. Most recurrences (n = 11) appeared within six weeks after surgery. CONCLUSIONS: Therapeutic keratoplasty may treat severe, refractory @entity4 effectively. High cure rates are achievable, although infection recurrence despite prolonged treatment remains a significant problem in @entity2 .

title: Therapeutic keratoplasty for advanced XXXX .

answer: @entity4


abstract: OBJECTIVE: The purpose of this study was to investigate whether the effect of treatment with hyaluronic acid (HA) on cartilage in @entity2 ( @entity2 ) can be determined by measuring the magnetic resonance (MR) T2 value of cartilage in an anterior cruciate ligament transection (ACLX) animal model. METHOD: Eighteen male @entity0 were separated randomly into three groups (n=6 for each group). Group 1 was given ACLX and intra-articular (IA) normal saline (NS) injection (ACLX+NS), group 2 was given ACLX and IA HA injection (ACLX+HA), and group 3 was the sham control. The ACLX+NS and ACLX+HA groups received ACLX on the right knee at 8 weeks of age and were then treated with IA NS or HA injection once a week, respectively, for 4 weeks starting at 13 weeks of age. In the sham-control group, the right knee joint was opened surgically but ACLX was not performed at 8 weeks of age. MR T2 measurements were obtained on all @entity0 at 8, 12, and 21 weeks of age, and histological Mankin scoring was performed at 21 weeks of age. RESULTS: Five weeks after the 4-week treatment, the MR T2 value of the ACLX right knee cartilage was significantly lower in ACLX+HA (29.58+/-1.12ms) than in ACLX+NS (32.04+/-1.39ms) (P<0.05). Five weeks after the 4-week treatment, the Mankin score of the ACLX right knee was significantly lower in ACLX+HA (3.3+/-0.81) than in ACLX+NS (7.3+/-1.03) (P<0.001). The T2 value was significantly and positively correlated with the Mankin score in the ACLX+NS (rho=0.77, P<0.05) and ACLX+HA (rho=0.69, P<0.05) groups. CONCLUSION: This study demonstrates the feasibility of quantitative MR T2 measurement in the early assessment of HA treatment efficiency in a @entity1 model.

title: Quantitative MR T2 measurement of articular cartilage to assess the treatment effect of intra-articular hyaluronic acid injection on experimental XXXX induced by ACLX.

answer: @entity2


abstract: OBJECTIVE: To investigate the effects of sex hormones on bladder and mechanism thereof. METHODS: Sixty mature female SD @entity0 underwent bilateral ovariectomy and then randomly divided into 6 groups: low dose @entity1 group (OVX + E group) treated with @entity8 0. 25 mg/kg injected intramuscularly qod, high dose @entity1 group (OVX + E 1 mg group) treated with @entity8 1 mg/kg, @entity5 (P) group, treated with P 1 mg, OVX + E + P group treated with @entity8 0.25 mg/kg + @entity5 1 mg, d @entity3 group (OVX + T group) treated with @entity7 3 mg/kg, and untreated ovariectomized group (OVX group) receiving no medication. Another 10 @entity0 underwent sham operation. Four weeks later the @entity0 were killed with their bladders and urethras taken out to undergo light and electron microscopy. RESULTS: The thickness of bladder wall of the OVX group was (0.97 +/- 0.11) mm, significant thinner than that of the sham operation group [(1.10 +/- 0.1) mm, P < 0.05)]. The thickness levels of bladder walls of the OVX + E and OVX + T groups were (1.23 +/- 0.12) mm and (1.26 +/- 0.12 mm) respectively, both significantly thicker than that of the OVX group (both P < 0.01). Wider spaces between the detrusor muscle fascicles and degeneration of detrusor muscle cells were seen in the bladder walls of the OVX group, and such phenomena were milder in the OVX + E and OVX + T groups, however, wider spaces between the detrusor muscle fascicles could be seen in the OVX + E + P group too. The @entity4 effect on the detrusor muscle of the OVX + E 1 mg group was weaker than that of the OVX + E group, a lot of cytoplasmic vacuoles was seen in the 2 groups treated with E, especially the OVX + E 1 mg group. The @entity6 of the OVX + P group was similar to that of the OVX group. CONCLUSION: Endogenous @entity2 level as well as @entity1 level can significantly affect the @entity6 with a @entity4 effect on bladder detrusor muscle. But higher doze of @entity1 also has some unexpected effects which may destroy @entity6 . In addition, @entity5 can compromise the effect of @entity1 .

title: [Effects of sex hormones on bladder function and structure: experiment with ovariectomized female XXXX ].

answer: @entity0


abstract: OBJECTIVE: To evaluate the reliability and validity of parent proxy-report scales of Pediatric Quality of Life Inventory Version 4.0 (PedsQL 4.0) Generic Core Scales, the Chinese Version. METHODS: 3493 school students aged 6-18 years were recruited using multistage cluster sampling method. Health-related quality of life was assessed using the above-mentioned PedsQL 4.0 scales. The internal consistency was assessed, using Cronbach's a coefficient, while its validity was tested through correlation analysis, t-test and exploratory factor analysis. RESULTS: The internal consistency reliability for Total Scale Score (Cronbach's alpha = 0.90), Physical Health Summary Score (alpha= 0.81), and Psychosocial Health Summary Score (alpha= 0.89) were excellent. Six major factors were extracted by factor analysis which basically matched the designed structure of the original version accounting for nearly 66% of the variance. The total Scale Score significantly decreased by 3.5 to 13.3 (P < 0.05) in @entity0 and adolescents who had diseases including cold, skin @entity1 , @entity5 , courbature or @entity4 , @entity3 with a frequency of 6 times or more per year or had @entity2 as compared to those with lower frequency (< or = 5 times/y) of the diseases or without @entity2 . We found moderate to high correlations between items and the subscales. Correlation coefficients ranged between 0.45 to 0.84 (P < 0.01). CONCLUSION: The reliability and validity of the parent proxy-report scales of PedsQL 4.0 Generic Core Scales of the Chinese Version were as good as the original version. Our findings suggested that the scales could be applied to evaluate the health-related quality of life in childhood @entity0 in similar Chinese regions to Guangzhou.

title: [Validity and reliability of Pediatric Quality of Life Inventory Version 4.0 Generic Core Scales in Chinese XXXX and adolescents].

answer: @entity0


abstract: All electroencephalograms performed in our institution between 1980 and 1990 were reviewed. The clinical characteristics of @entity0 with @entity1 and generalized spike-and-wave (SW) patterns were analyzed. The SW patterns were classified according to their frequency. Electroencephalograms of 154 @entity0 with @entity1 revealed SW patterns. Absence @entity2 were the most common first @entity2 , but partial @entity2 were frequent. More than 40% had several types of @entity2 . Sixty percent of the @entity1 syndromes were generalized, but almost 25% were partial. The typical SW pattern was associated with @entity4 , a normal examination and computed tomographic scan, @entity5 , monotherapy, freedom from @entity2 , and lack of recurrence. The slow SW pattern was associated with @entity3 ; a younger age at @entity2 onset; atonic, @entity2 ; an abnormal examination and computed tomographic scan; cryptogenic or symptomatic generalized @entity1 or symptomatic partial @entity1 ; polytherapy; and poor @entity2 control. The fast SW pattern was associated with secondary generalized, partial, @entity2 ; a normal computed tomographic scan; cryptogenic partial @entity1 ; @entity2 ; and @entity2 recurrence. @entity1 with a typical SW pattern should be considered benign, @entity1 with a slow SW pattern malignant, and @entity1 with a fast SW pattern treacherous.

title: Generalized spike-and-wave patterns in XXXX : clinical correlates.

answer: @entity0


abstract: BACKGROUND: Currently, @entity1 grade is the best predictor of outcome at first presentation of noninvasive @entity3 . However, reliable predictors of @entity1 recurrence and progression for individual @entity0 , which could optimize treatment and follow-up schedules based on specific @entity1 biology, are yet to be identified. OBJECTIVE: To identify genes predictive for recurrence and progression in Ta @entity3 at first presentation using a quantitative, pathway-specific approach. DESIGN, SETTING, AND @entity0 : Retrospective study of @entity0 with Ta G2/3 @entity3 at initial presentation with three distinct clinical outcomes: absence of recurrence (n=16), recurrence without progression (n=16), and progression to @entity4 in situ or invasive disease (n=16). MEASUREMENTS: Expressions of 24 genes that feature in relevant pathways that are deregulated in @entity3 were quantified by real-time polymerase chain reaction on @entity1 biopsies from the @entity0 at initial presentation. RESULTS AND LIMITATIONS: @entity8 (p=0.003) and @entity6 (p=0.01) were predictive for recurrence by univariate analysis. In a multivariable model based on @entity8 expression, sensitivity and specificity for recurrence were 97% and 63%, respectively. @entity6 (p<0.001), @entity7 (p=0.017), @entity9 /Survivin (p=0.038), and @entity5 (p=0.047) were predictive for progression by univariate analysis. Multivariable analysis based on @entity6 , @entity5 , and @entity2 identified progression with 81% sensitivity and 94% specificity. Since this is a small retrospective study using medium-throughput profiling, larger confirmatory studies are needed. CONCLUSIONS: Gene expression profiling across relevant @entity1 pathways appears to be a promising approach for Ta @entity3 outcome prediction at initial diagnosis. These results could help differentiate between @entity0 who need aggressive versus expectant management.

title: Predicting recurrence and progression of noninvasive XXXX at initial presentation based on quantitative gene expression profiles.

answer: @entity3


abstract: PURPOSE: Nepafenac ophthalmic suspension 0.1% was dosed topically once (QD), twice ( @entity5 ), or three-times (TID) daily to assess the resolution of @entity4 and anterior-segment @entity1 following @entity3 surgery. METHODS: This was a prospective, multicenter, double-masked, randomized, placebo-controlled study of 212 adults. @entity0 received nepafenac 0.1% or placebo, 1 drop QD, @entity5 , or TID beginning 1 day before @entity3 surgery, continuing on the day of surgery, and for 14 days thereafter. One (1) additional drop was administered 30-120 min prior to surgery. The primary efficacy endpoint was percent of treatment failures (>or=16 aqueous cells, aqueous flare = severe, or @entity4 score = moderately severe or severe) through postoperative day 14. RESULTS: On days 7 and 14, the QD, @entity5 , and TID all nepafenac posologies significantly reduced the percent of treatment failures, compared to placebo ( p <or= 0.0029). Compared with placebo, the TID posology achieved statistical significance beginning on day 3 ( p <or= 0.0080). Nepafenac treatment significantly increased the proportion of @entity0 with @entity1 , compared to placebo, beginning on day 1 for TID dosing ( p <or= 0.0208) and beginning on day 3 for QD dosing ( p <or= 0.0483). A significantly greater percentage of nepafenac-treated @entity0 were @entity2 free, compared to placebo, beginning on postoperative day 1 with @entity5 and TID dosing ( p <or= 0.0150) and beginning on day 3 for QD dosing (p <or= 0.0220). No serious ocular adverse events were reported, and fewer @entity0 experienced adverse events in the nepafenac groups than in the placebo group. CONCLUSIONS: Nepafenac ophthalmic suspension 0.1% was well tolerated and effectively @entity1 and increased the incidence of @entity4 -free @entity0 following @entity3 surgery when dosed QD, @entity5 , or TID. By postoperative day 14, all nepafenac posologies significantly reduced the incidence of treatment failures and the incidence of @entity0 presenting with @entity1 , and significantly increased the incidence of @entity4 -free @entity0 relative to placebo.

title: Nepafenac dosing frequency for XXXX and @entity1 associated with @entity3 surgery.

answer: @entity4


abstract: PURPOSE: Nepafenac ophthalmic suspension 0.1% was dosed topically once (QD), twice ( @entity5 ), or three-times (TID) daily to assess the resolution of @entity4 and anterior-segment @entity1 following @entity3 surgery. METHODS: This was a prospective, multicenter, double-masked, randomized, placebo-controlled study of 212 adults. @entity0 received nepafenac 0.1% or placebo, 1 drop QD, @entity5 , or TID beginning 1 day before @entity3 surgery, continuing on the day of surgery, and for 14 days thereafter. One (1) additional drop was administered 30-120 min prior to surgery. The primary efficacy endpoint was percent of treatment failures (>or=16 aqueous cells, aqueous flare = severe, or @entity4 score = moderately severe or severe) through postoperative day 14. RESULTS: On days 7 and 14, the QD, @entity5 , and TID all nepafenac posologies significantly reduced the percent of treatment failures, compared to placebo ( p <or= 0.0029). Compared with placebo, the TID posology achieved statistical significance beginning on day 3 ( p <or= 0.0080). Nepafenac treatment significantly increased the proportion of @entity0 with @entity1 , compared to placebo, beginning on day 1 for TID dosing ( p <or= 0.0208) and beginning on day 3 for QD dosing ( p <or= 0.0483). A significantly greater percentage of nepafenac-treated @entity0 were @entity2 free, compared to placebo, beginning on postoperative day 1 with @entity5 and TID dosing ( p <or= 0.0150) and beginning on day 3 for QD dosing (p <or= 0.0220). No serious ocular adverse events were reported, and fewer @entity0 experienced adverse events in the nepafenac groups than in the placebo group. CONCLUSIONS: Nepafenac ophthalmic suspension 0.1% was well tolerated and effectively @entity1 and increased the incidence of @entity4 -free @entity0 following @entity3 surgery when dosed QD, @entity5 , or TID. By postoperative day 14, all nepafenac posologies significantly reduced the incidence of treatment failures and the incidence of @entity0 presenting with @entity1 , and significantly increased the incidence of @entity4 -free @entity0 relative to placebo.

title: Nepafenac dosing frequency for @entity4 and @entity1 associated with XXXX surgery.

answer: @entity3


abstract: PURPOSE: Nepafenac ophthalmic suspension 0.1% was dosed topically once (QD), twice ( @entity5 ), or three-times (TID) daily to assess the resolution of @entity4 and anterior-segment @entity1 following @entity3 surgery. METHODS: This was a prospective, multicenter, double-masked, randomized, placebo-controlled study of 212 adults. @entity0 received nepafenac 0.1% or placebo, 1 drop QD, @entity5 , or TID beginning 1 day before @entity3 surgery, continuing on the day of surgery, and for 14 days thereafter. One (1) additional drop was administered 30-120 min prior to surgery. The primary efficacy endpoint was percent of treatment failures (>or=16 aqueous cells, aqueous flare = severe, or @entity4 score = moderately severe or severe) through postoperative day 14. RESULTS: On days 7 and 14, the QD, @entity5 , and TID all nepafenac posologies significantly reduced the percent of treatment failures, compared to placebo ( p <or= 0.0029). Compared with placebo, the TID posology achieved statistical significance beginning on day 3 ( p <or= 0.0080). Nepafenac treatment significantly increased the proportion of @entity0 with @entity1 , compared to placebo, beginning on day 1 for TID dosing ( p <or= 0.0208) and beginning on day 3 for QD dosing ( p <or= 0.0483). A significantly greater percentage of nepafenac-treated @entity0 were @entity2 free, compared to placebo, beginning on postoperative day 1 with @entity5 and TID dosing ( p <or= 0.0150) and beginning on day 3 for QD dosing (p <or= 0.0220). No serious ocular adverse events were reported, and fewer @entity0 experienced adverse events in the nepafenac groups than in the placebo group. CONCLUSIONS: Nepafenac ophthalmic suspension 0.1% was well tolerated and effectively @entity1 and increased the incidence of @entity4 -free @entity0 following @entity3 surgery when dosed QD, @entity5 , or TID. By postoperative day 14, all nepafenac posologies significantly reduced the incidence of treatment failures and the incidence of @entity0 presenting with @entity1 , and significantly increased the incidence of @entity4 -free @entity0 relative to placebo.

title: Nepafenac dosing frequency for @entity4 and XXXX associated with @entity3 surgery.

answer: @entity1


abstract: We studied the effects of intracolonic administration of opioid receptor agonists (ORAs) on responses of pelvic nerve afferent fibers to @entity0 ( @entity0 ) and heat. Single-fiber recordings were made from the decentralized S1 dorsal rootlet in the @entity1 . An approximately 7-cm length of descending colon was isolated in situ to permit intracolonic perfusion with Krebs solution, which, when the outflow was clamped, was used to distend the colon. Responses to noxious @entity0 (40 mmHg, 30 s) were tested after intracolonic instillation of mu-, delta- or kappa-ORAs. Intracolonic administration of the kappa-ORAs EMD 61,753 (n = 5/12) and U62,066 (n = 8/11), but not either the mu-ORA @entity2 or the delta-ORA @entity3 , concentration-dependently inhibited responses of afferent fibers. For fibers unaffected by intracolonic administration of EMD 61,753 or U62,066, intra-arterial administration of kappa-ORAs was effective. Forty-one of 54 mechanosensitive fibers also responded to intracolonic instillation of heated Krebs solution (50 degrees C). Intra-arterial injection of @entity2 or @entity3 did not attenuate responses to heat. Either intracolonic or intra-arterial administration of EMD 61,753 or U62, 066, however, inhibited afferent fiber responses to heat. These results document that mechanical and thermal sensitivity of polymodal pelvic nerve afferent fibers innervating the @entity1 colon can be inhibited peripherally by intracolonic instillation of kappa-ORAs.

title: Effects of intracolonic opioid receptor agonists on polymodal pelvic nerve afferent fibers in the XXXX .

answer: @entity1


abstract: OBJECTIVES: This article is to study the role of G(1)/S regulators in differentiation of pluripotent embryonic cells. MATERIALS AND METHODS: We established a @entity5 @entity1 cell-based experimental system, which profits from two similar differentiation protocols producing endodermal or neuroectodermal lineages. The levels, mutual interactions, activities, and localization of G(1)/S regulators were analysed with respect to growth and differentiation parameters of the cells. RESULTS AND CONCLUSIONS: We demonstrate that proliferation parameters of differentiating cells correlate with the activity and structure of @entity3 /E- @entity9 but not of cyclin D- @entity10 - @entity6 complexes. In an exponentially growing @entity5 cell population, the @entity2 - @entity7 complex is detected, which is replaced by @entity4 /3- @entity10 - @entity6 complex following density arrest. During endodermal differentiation kinase-inactive @entity4 /D3- @entity7 - @entity6 complexes are formed. Neural differentiation specifically induces @entity2 at the expense of @entity11 and results in predominant formation of @entity2 /D2- @entity7 - @entity6 complexes. Differentiation is accompanied by cytoplasmic accumulation of cyclin Ds and @entity10 , which in neural cells are associated with neural outgrowths. Most phenomena found here can be reproduced in @entity0 embryonic stem cells. In summary, our data demonstrate (i) that individual cyclin D isoforms are utilized in cells lineage specifically, (ii) that fundamental difference in the function of @entity7 and @entity8 exists, and (iii) that cyclin D- @entity10 complexes function in the cytoplasm of differentiated cells. Our study unravels another level of complexity in G(1)/S transition-regulating machinery in early embryonic cells.

title: Lineage specific composition of cyclin D- @entity7 / @entity8 - XXXX complexes reveals distinct functions of @entity7 , @entity8 and individual D-type cyclins in differentiating cells of embryonic origin.

answer: @entity6


abstract: OBJECTIVES: This article is to study the role of G(1)/S regulators in differentiation of pluripotent embryonic cells. MATERIALS AND METHODS: We established a @entity5 @entity1 cell-based experimental system, which profits from two similar differentiation protocols producing endodermal or neuroectodermal lineages. The levels, mutual interactions, activities, and localization of G(1)/S regulators were analysed with respect to growth and differentiation parameters of the cells. RESULTS AND CONCLUSIONS: We demonstrate that proliferation parameters of differentiating cells correlate with the activity and structure of @entity3 /E- @entity9 but not of cyclin D- @entity10 - @entity6 complexes. In an exponentially growing @entity5 cell population, the @entity2 - @entity7 complex is detected, which is replaced by @entity4 /3- @entity10 - @entity6 complex following density arrest. During endodermal differentiation kinase-inactive @entity4 /D3- @entity7 - @entity6 complexes are formed. Neural differentiation specifically induces @entity2 at the expense of @entity11 and results in predominant formation of @entity2 /D2- @entity7 - @entity6 complexes. Differentiation is accompanied by cytoplasmic accumulation of cyclin Ds and @entity10 , which in neural cells are associated with neural outgrowths. Most phenomena found here can be reproduced in @entity0 embryonic stem cells. In summary, our data demonstrate (i) that individual cyclin D isoforms are utilized in cells lineage specifically, (ii) that fundamental difference in the function of @entity7 and @entity8 exists, and (iii) that cyclin D- @entity10 complexes function in the cytoplasm of differentiated cells. Our study unravels another level of complexity in G(1)/S transition-regulating machinery in early embryonic cells.

title: Lineage specific composition of cyclin D- XXXX / @entity8 - @entity6 complexes reveals distinct functions of @entity7 , @entity8 and individual D-type cyclins in differentiating cells of embryonic origin.

answer: @entity7


abstract: OBJECTIVES: This article is to study the role of G(1)/S regulators in differentiation of pluripotent embryonic cells. MATERIALS AND METHODS: We established a @entity5 @entity1 cell-based experimental system, which profits from two similar differentiation protocols producing endodermal or neuroectodermal lineages. The levels, mutual interactions, activities, and localization of G(1)/S regulators were analysed with respect to growth and differentiation parameters of the cells. RESULTS AND CONCLUSIONS: We demonstrate that proliferation parameters of differentiating cells correlate with the activity and structure of @entity3 /E- @entity9 but not of cyclin D- @entity10 - @entity6 complexes. In an exponentially growing @entity5 cell population, the @entity2 - @entity7 complex is detected, which is replaced by @entity4 /3- @entity10 - @entity6 complex following density arrest. During endodermal differentiation kinase-inactive @entity4 /D3- @entity7 - @entity6 complexes are formed. Neural differentiation specifically induces @entity2 at the expense of @entity11 and results in predominant formation of @entity2 /D2- @entity7 - @entity6 complexes. Differentiation is accompanied by cytoplasmic accumulation of cyclin Ds and @entity10 , which in neural cells are associated with neural outgrowths. Most phenomena found here can be reproduced in @entity0 embryonic stem cells. In summary, our data demonstrate (i) that individual cyclin D isoforms are utilized in cells lineage specifically, (ii) that fundamental difference in the function of @entity7 and @entity8 exists, and (iii) that cyclin D- @entity10 complexes function in the cytoplasm of differentiated cells. Our study unravels another level of complexity in G(1)/S transition-regulating machinery in early embryonic cells.

title: Lineage specific composition of cyclin D- @entity7 / @entity8 - @entity6 complexes reveals distinct functions of XXXX , @entity8 and individual D-type cyclins in differentiating cells of embryonic origin.

answer: @entity7


abstract: OBJECTIVES: This article is to study the role of G(1)/S regulators in differentiation of pluripotent embryonic cells. MATERIALS AND METHODS: We established a @entity5 @entity1 cell-based experimental system, which profits from two similar differentiation protocols producing endodermal or neuroectodermal lineages. The levels, mutual interactions, activities, and localization of G(1)/S regulators were analysed with respect to growth and differentiation parameters of the cells. RESULTS AND CONCLUSIONS: We demonstrate that proliferation parameters of differentiating cells correlate with the activity and structure of @entity3 /E- @entity9 but not of cyclin D- @entity10 - @entity6 complexes. In an exponentially growing @entity5 cell population, the @entity2 - @entity7 complex is detected, which is replaced by @entity4 /3- @entity10 - @entity6 complex following density arrest. During endodermal differentiation kinase-inactive @entity4 /D3- @entity7 - @entity6 complexes are formed. Neural differentiation specifically induces @entity2 at the expense of @entity11 and results in predominant formation of @entity2 /D2- @entity7 - @entity6 complexes. Differentiation is accompanied by cytoplasmic accumulation of cyclin Ds and @entity10 , which in neural cells are associated with neural outgrowths. Most phenomena found here can be reproduced in @entity0 embryonic stem cells. In summary, our data demonstrate (i) that individual cyclin D isoforms are utilized in cells lineage specifically, (ii) that fundamental difference in the function of @entity7 and @entity8 exists, and (iii) that cyclin D- @entity10 complexes function in the cytoplasm of differentiated cells. Our study unravels another level of complexity in G(1)/S transition-regulating machinery in early embryonic cells.

title: Lineage specific composition of cyclin D- @entity7 / XXXX - @entity6 complexes reveals distinct functions of @entity7 , @entity8 and individual D-type cyclins in differentiating cells of embryonic origin.

answer: @entity8


abstract: OBJECTIVES: This article is to study the role of G(1)/S regulators in differentiation of pluripotent embryonic cells. MATERIALS AND METHODS: We established a @entity5 @entity1 cell-based experimental system, which profits from two similar differentiation protocols producing endodermal or neuroectodermal lineages. The levels, mutual interactions, activities, and localization of G(1)/S regulators were analysed with respect to growth and differentiation parameters of the cells. RESULTS AND CONCLUSIONS: We demonstrate that proliferation parameters of differentiating cells correlate with the activity and structure of @entity3 /E- @entity9 but not of cyclin D- @entity10 - @entity6 complexes. In an exponentially growing @entity5 cell population, the @entity2 - @entity7 complex is detected, which is replaced by @entity4 /3- @entity10 - @entity6 complex following density arrest. During endodermal differentiation kinase-inactive @entity4 /D3- @entity7 - @entity6 complexes are formed. Neural differentiation specifically induces @entity2 at the expense of @entity11 and results in predominant formation of @entity2 /D2- @entity7 - @entity6 complexes. Differentiation is accompanied by cytoplasmic accumulation of cyclin Ds and @entity10 , which in neural cells are associated with neural outgrowths. Most phenomena found here can be reproduced in @entity0 embryonic stem cells. In summary, our data demonstrate (i) that individual cyclin D isoforms are utilized in cells lineage specifically, (ii) that fundamental difference in the function of @entity7 and @entity8 exists, and (iii) that cyclin D- @entity10 complexes function in the cytoplasm of differentiated cells. Our study unravels another level of complexity in G(1)/S transition-regulating machinery in early embryonic cells.

title: Lineage specific composition of cyclin D- @entity7 / @entity8 - @entity6 complexes reveals distinct functions of @entity7 , XXXX and individual D-type cyclins in differentiating cells of embryonic origin.

answer: @entity8


abstract: STUDY OBJECTIVES: The purpose of this phase III clinical trial was to test whether chemotherapy followed by radiation therapy resulted in superior survival to either hyperfractionated radiation or standard radiation in surgically unresectable @entity2 . DESIGN: @entity0 were prospectively randomized to 2 months of @entity1 , @entity3 chemotherapy followed by 60 Gy of radiation at 2.0 Gy per fraction or 1.2 Gy per fraction radiation delivered twice daily to a total dose of 69.6 Gy, or 2.0 Gy per fraction of radiation once daily to 60 Gy. @entity0 were enrolled from January 1989 through January 1992, and followed for a potential minimum period of 5 years. SETTING: This trial was an intergroup National Cancer Institute-funded trial within the Radiation Therapy Oncology Group, the Eastern Cooperative Oncology Group, and the Southwest Oncology Group. @entity0 : @entity0 with surgically unresectable @entity2 , clinical stage II, IIIA, and IIIB, were required to have a Karnofsky Performance Status of > or = 70 and a weight loss of < 5% for 3 months before study entry. Four hundred ninety @entity0 were registered on trial, of which 458 @entity0 were eligible. CONCLUSION: Overall survival was statistically superior for the @entity0 receiving chemotherapy and radiation vs the other two arms of the study. The twice-daily radiation therapy arm, although better, was not statistically superior in survival for those @entity0 receiving standard radiation. Median survival for standard radiation was 11.4 months; for chemotherapy and @entity4 , 13.2 months; and for hyperfractionated @entity4 , 12 months. The respective 5-year survivals were 5% for standard radiation therapy, 8% for chemotherapy followed by radiation therapy, and 6% for hyperfractionated @entity4 .

title: Final results of phase III trial in regionally advanced unresectable XXXX : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.

answer: @entity2


abstract: BACKGROUND: Little is known about the effect of migrant status on @entity1 survival. We studied @entity1 survival among @entity0 of Turkish descent in the German Cancer Childhood Registry, one of the largest @entity1 registries worldwide. METHODS: We identified @entity0 of Turkish descent among @entity1 cases using a name-based approach. We compared 5-year survival probabilities of Turkish and other @entity0 in three time periods of diagnosis (1980-87, 1988-95, 1996-2005) using the Kaplan-Meier method and log-rank tests. RESULTS: The 5-year survival probability for all @entity1 among 1774 cases of Turkish descent (4.76% of all 37.259 cases) was 76.9% compared to 77.6% in the comparison group (all other cases; p = 0.15). We found no age- or sex-specific survival differences (p-values between p = 0.18 and p = 0.90). For the period 1980-87, the 5-year survival probability among Turkish @entity0 with @entity2 was significantly lower (62% versus 75.8%; p < 0.0001), this remains unexplained. For more recently diagnosed @entity2 , we saw no survival differences for Turkish and non-Turkish @entity0 . CONCLUSION: Our results suggest that nowadays Turkish migrant status has no bearing on the outcome of @entity1 therapies in Germany. The inclusion of currently more than 95% of all @entity1 cases in standardised treatment protocols is likely to contribute to this finding.

title: Cancer survival among XXXX of Turkish descent in Germany 1980-2005: a registry-based analysis.

answer: @entity0


abstract: @entity3 are uncommon but potentially life-threatening anomalies of @entity0 and @entity0 . Between 1970 and 1988, 45 @entity0 from birth to 13 years of age (23 @entity0 and 22 @entity0 ) underwent evaluation and treatment for @entity3 . Thirty-seven had solitary lesions: bronchogenic cyst (n = 13), @entity7 (n = 9), @entity8 (n = 6), @entity9 (n = 6), @entity5 (n = 2), and @entity4 (n = 1). Eight additional @entity0 had two simultaneous abnormalities and three @entity0 had @entity6 . Twenty-one @entity0 had respiratory symptoms, which were severe in seven. Twelve had @entity2 and 10 @entity0 were completely free of symptoms. Plain chest roentgenogram was the only diagnostic imaging performed in 11 @entity0 . Thirteen @entity0 underwent computed tomographic scan, but in only four was it essential for diagnosis. Prenatal ultrasonography in three @entity0 demonstrated @entity7 in two, with one false negative study. Postnatally, ultrasonography was also useful in establishing the diagnoses of @entity7 and @entity9 . Thoracotomy with excision of the lesion by lobectomy or pneumonectomy resulted in survival of 42 @entity0 (93%). Three deaths in neonates were due to @entity2 and @entity1 . Two of them had concomitant @entity6 ; the other had a @entity7 and died despite the use of postoperative extracorporeal membrane oxygenation. These data demonstrate that @entity3 usually can be diagnosed by plain chest x-ray films. Ancillary studies such as ultrasonography or computed tomography may occasionally be necessary. Combinations of the different types of @entity3 occurred frequently. All lesions, including symptomatic lesions in neonates, can be managed surgically soon after diagnosis.

title: XXXX . Diagnostic and therapeutic considerations.

answer: @entity3


abstract: BACKGROUND: Quantitative analysis of left-ventricular (LV) @entity1 after @entity2 is prognostically relevant and assists in planning surgery. Three-dimensional (3D) echocardiography facilitates clear visualization of cardiac anatomy and accurate assessment of functional parameters. The aim of the present study was to determine the ability of 3D echocardiography to quantify LV @entity1 . METHODS: Ten @entity0 with a known @entity3 after @entity2 underwent 3D echocardiography and cardiac magnetic resonance (CMR) imaging at 1.5 Tesla within 3 days. For 3D echocardiography, a multiplanar transesophageal examination was performed with full LV coverage and the 3D dataset was analyzed offline. The @entity3 was defined by a wall thickness <5 mm. The following quantitative parameters were determined: left ventricular end-diastolic and end-systolic volumes, LV myocardial mass (LV-mass) and mass of the @entity3 . LV ejection fraction and percentage of @entity1 mass (%- @entity1 ) were calculated. RESULTS: LV volumes and ejection fraction showed a strong correlation between 3D echocardiography and CMR (r = 0.94-0.97; P < 0.01). Importantly, the mass and percentage of mass of the @entity3 demonstrated a high correlation as well (r = 0.94 and r = 0.86, respectively; P < 0.01). For all parameters, the calculated bias between both methods was found to be minimal (0.8-7.6%). CONCLUSIONS: Three-dimensional echocardiography proved to be a reliable tool for quantitative analysis of LV volumes, ejection fraction and @entity1 size in @entity0 with prior @entity2 . In addition, 3D visualization of the complex cardiac anatomy in @entity0 with @entity3 may assist surgical procedure planning.

title: Three-dimensional echocardiography for quantitative analysis of XXXX .

answer: @entity3


abstract: A case-control study on @entity2 was conducted in New Caledonia (South Pacific), where a high incidence of @entity5 had been observed. The disease pattern suggested an environmental exposure to @entity3 . The first results showed that, in some areas, tremolite @entity3 derived from local outcroppings was used as whitewash (locally named "p  "). All cases diagnosed between 1993 and 1995 (including 15 @entity4 , 228 @entity1 , and 23 @entity2 ) and 305 controls were included in the study. Detailed information on past or present use of the whitewash, residential history, smoking, diet, and occupation was collected. The risk of @entity4 was strongly associated with the use of the whitewash (odds ratio (OR) = 40.9; 95% confidence interval (CI): 5.15, 325). All Melanesian cases had been exposed. Among Melanesian @entity0 , exposure to the whitewash was associated with an increased risk of @entity1 (OR = 4.89; 95% CI: 1.13, 21.2), and smokers exposed to po had an approximately ninefold risk (OR = 9.26; 95% CI: 1.72, 49.7) compared with @entity0 who never smoked and had never used the whitewash. In contrast, no association was noted between exposure to p   and @entity1 risk among Melanesian @entity0 , probably because of lower exposure levels. Among non-Melanesians, the numbers of exposed subjects were too small to assess the effect of exposure to po. There was no indication of elevated risks for the other @entity2 sites.

title: Environmental exposure to XXXX in New Caledonia: a case-control study.

answer: @entity2


abstract: BACKGROUND _ AIMS: @entity2 ( @entity2 ) often leads to the development of @entity1 . To understand better this pathogenic mechanism, we investigated whether islet cell area and pancreatic volume are reduced in @entity2 @entity0 , islet cell turnover increases in @entity2 @entity0 , and islet cells are less vulnerable to apoptosis than acinar cells. METHODS: Pancreatic tissues from 43 @entity0 with @entity2 and 27 controls were examined by immunohistochemistry and quantitative morphometry. Pancreas volume was determined using abdominal computed tomography data. RESULTS: The pancreatic volumes were 64.9 +/- 4.3 cm(3) in @entity2 @entity0 and 82.3 +/- 6.7 cm(3) in controls (P = .035). beta-cell areas were 0.69% +/- 0.08% in @entity2 @entity0 and 0.97% +/- 0.08% in controls (P = .017), whereas alpha-cell areas did not differ between the groups (P = .47). There were no differences in the frequencies of replication among groups of alpha-cells, beta-cells, duct cells, or acinar cells nor were there differences in numbers of apoptotic alpha-cells or beta-cells between @entity2 @entity0 and controls. However, @entity2 @entity0 had an approximately 10-fold increase in numbers of apoptotic acinar cells compared with controls (P < .0001). CONCLUSIONS: Pancreatic volume was reduced by 21%, and the area comprising beta-cells was reduced by 29% in @entity0 with @entity2 . The lack of increased beta-cells turnover in @entity2 @entity0 , despite an approximately 10-fold increase in the number of apoptotic acinar cells, suggests that the damage to the pancreas is highly specific for the exocrine compartment and affects the endocrine islets to a lesser extent.

title: Reduced pancreatic volume and beta-cell area in XXXX with chronic pancreatitis.

answer: @entity0


abstract: SUMMARY: The use of @entity5 (SRL) in orthotopic liver transplantation (OLT) has been controversial after experimental data suggested an increased risk of @entity3 ( @entity3 ). To assess the safety and efficacy of SRL as de novo immunosuppression in OLT recipients. Outcomes of 252 OLT @entity0 who received SRL were compared with outcomes of 291 OLT recipients who received @entity6 in a retrospective study. Primary outcomes of this study were: @entity0 - and graft survivals, vascular, biliary, wound complications and rejection rates. Secondary outcomes were: @entity1 rate, bone marrow and renal function and changes of lipid levels. @entity0 - and graft survivals, rejection and infection rates were similar. In the SRL group, @entity3 occurred in 1.2%, biliary complications in 19.4%, and incisional hernias in 9.1%. In the control group the incidence of @entity3 was 5.8% (P = 0.004), biliary complications 18.5% (P = NS) and @entity2 .2% (P = NS). @entity0 on SRL experienced significantly higher levels of serum @entity4 but fewer acute cellular rejections. Bone marrow and renal functions were similar in both the groups. Our findings would suggest that SRL is safe and effective for very selected OLT recipients. Randomized controlled trials are necessary to confirm our results.

title: Multicentric outcome analysis of XXXX -based immunosuppression in 252 liver transplant recipients.

answer: @entity5


abstract: BACKGROUND: In @entity5 ( @entity5 ), an overactive @entity2 ( @entity2 ) pathway is a component of the malignant phenotype. Two @entity3 kinase inhibitors (TKIs) of @entity2 , gefinitib and @entity7 , have been used with variable benefit. METHODS: We have analyzed outcome data of a population of @entity5 @entity0 that received these TKIs to determine the benefit derived and to define the clinical and molecular parameters that correlate with response. @entity1 tissue from a subgroup of these @entity0 was analyzed by immunohistochemistry to measure the expression level of @entity2 and four activated (phosphorylated) members of the pathway, pEGFR, @entity9 , pAKT, and pSTAT3. RESULTS: @entity7 was slightly superior to @entity8 in all measures of response, although the differences were not statistically significant. The most robust clinical predictors of @entity4 ( @entity4 ) were best response and @entity6 (p < 0.0001). A higher level of pEGFR was associated with longer @entity4 , while the total @entity2 level was not associated with response. Higher levels of pAKT and pSTAT3 were also associated with longer @entity4 . In contrast, a higher level of pERK1/2 was associated with shorter @entity4 . CONCLUSION: These observations suggest the hypothesis that @entity1 cells that have activated @entity2 pathways, presumably being utilized for survival, are clinically relevant targets for pathway inhibition. An accurate molecular predictive model of TKI response should include activated members of the @entity2 pathway. TKIs may be best reserved for @entity1 expressing pEGFR and pAKT or pSTAT, and little @entity9 . In the absence of molecular predictors of response, the appearance of a @entity6 and a positive first scan are good clinical indicators of response.

title: Response to @entity8 and @entity7 in XXXX : a restrospective study.

answer: @entity5


abstract: BACKGROUND: In @entity5 ( @entity5 ), an overactive @entity2 ( @entity2 ) pathway is a component of the malignant phenotype. Two @entity3 kinase inhibitors (TKIs) of @entity2 , gefinitib and @entity7 , have been used with variable benefit. METHODS: We have analyzed outcome data of a population of @entity5 @entity0 that received these TKIs to determine the benefit derived and to define the clinical and molecular parameters that correlate with response. @entity1 tissue from a subgroup of these @entity0 was analyzed by immunohistochemistry to measure the expression level of @entity2 and four activated (phosphorylated) members of the pathway, pEGFR, @entity9 , pAKT, and pSTAT3. RESULTS: @entity7 was slightly superior to @entity8 in all measures of response, although the differences were not statistically significant. The most robust clinical predictors of @entity4 ( @entity4 ) were best response and @entity6 (p < 0.0001). A higher level of pEGFR was associated with longer @entity4 , while the total @entity2 level was not associated with response. Higher levels of pAKT and pSTAT3 were also associated with longer @entity4 . In contrast, a higher level of pERK1/2 was associated with shorter @entity4 . CONCLUSION: These observations suggest the hypothesis that @entity1 cells that have activated @entity2 pathways, presumably being utilized for survival, are clinically relevant targets for pathway inhibition. An accurate molecular predictive model of TKI response should include activated members of the @entity2 pathway. TKIs may be best reserved for @entity1 expressing pEGFR and pAKT or pSTAT, and little @entity9 . In the absence of molecular predictors of response, the appearance of a @entity6 and a positive first scan are good clinical indicators of response.

title: Response to @entity8 and XXXX in @entity5 : a restrospective study.

answer: @entity7


abstract: BACKGROUND: In @entity5 ( @entity5 ), an overactive @entity2 ( @entity2 ) pathway is a component of the malignant phenotype. Two @entity3 kinase inhibitors (TKIs) of @entity2 , gefinitib and @entity7 , have been used with variable benefit. METHODS: We have analyzed outcome data of a population of @entity5 @entity0 that received these TKIs to determine the benefit derived and to define the clinical and molecular parameters that correlate with response. @entity1 tissue from a subgroup of these @entity0 was analyzed by immunohistochemistry to measure the expression level of @entity2 and four activated (phosphorylated) members of the pathway, pEGFR, @entity9 , pAKT, and pSTAT3. RESULTS: @entity7 was slightly superior to @entity8 in all measures of response, although the differences were not statistically significant. The most robust clinical predictors of @entity4 ( @entity4 ) were best response and @entity6 (p < 0.0001). A higher level of pEGFR was associated with longer @entity4 , while the total @entity2 level was not associated with response. Higher levels of pAKT and pSTAT3 were also associated with longer @entity4 . In contrast, a higher level of pERK1/2 was associated with shorter @entity4 . CONCLUSION: These observations suggest the hypothesis that @entity1 cells that have activated @entity2 pathways, presumably being utilized for survival, are clinically relevant targets for pathway inhibition. An accurate molecular predictive model of TKI response should include activated members of the @entity2 pathway. TKIs may be best reserved for @entity1 expressing pEGFR and pAKT or pSTAT, and little @entity9 . In the absence of molecular predictors of response, the appearance of a @entity6 and a positive first scan are good clinical indicators of response.

title: Response to XXXX and @entity7 in @entity5 : a restrospective study.

answer: @entity8


abstract: BACKGROUND: The Beck Depression Inventory (BDI) is frequently employed as measure of @entity2 in studies of @entity1 . The aim of the study was to assess the factorial structure of the BDI in @entity1 @entity0 prior to bariatric surgery. METHODS: Confirmatory factor analysis was conducted on the current published factor analyses of the BDI. Three published models were initially analysed with two additional modified models subsequently included. A sample of 285 @entity0 presenting for @entity4 -Band surgery was used. RESULTS: The published bariatric model by Munoz et al. was not an adequate fit to the data. The general model by Shafer et al. was a good fit to the data but had substantial limitations. The @entity3 item did not significantly load on any factor in either model. A modified Shafer model and a proposed model were tested, and both were found to be a good fit to the data with minimal differences between the two. A proposed model, in which two items, @entity3 and appetite, were omitted, was suggested to be the better model with good reliability. CONCLUSIONS: The previously published factor analysis in bariatric candidates by Munoz et al. was a poor fit to the data, and use of this factor structure should be seriously reconsidered within the @entity1 population. The hypothesised model was the best fit to the data. The findings of the study suggest that the existing published models are not adequate for investigating @entity2 in @entity1 @entity0 seeking surgery.

title: Confirmatory factor analysis of the Beck XXXX individuals seeking surgery.

answer: @entity2


abstract: Amplification of the @entity2 gene, present in 15-30% of @entity0 , correlates with poor outcome and is an indication for treatment with trastuzumab. Standard testing methods for @entity2 amplification are fluorescence (FISH) or chromogenic in situ hybridization (CISH). In FISH/CISH scoring, correction for chromosome 17 polysomy is believed to be critical for determination of true @entity2 amplification as opposed to increased chromosome 17 copy number. The term "polysomy 17" is widely used and defined as > or =3 copies of the chromosome 17 centromere (probe CEP17, D17Z1). Thus, the centromere is assumed to be representative for the entire chromosome. This study aimed to investigate the frequency of polysomy 17 and its association with @entity2 amplification in 111 invasive @entity0 @entity1 by CEP17 CISH and by copy number analysis of a set of 17 genes along chromosome 17 using multiplex ligation-dependent probe amplification (MLPA).Chromosome 17 usually showed a complex pattern of gains and losses by MLPA, unrelated to the copy number status of the centromere. Increase in centromere 17 copy number ( @entity3 "), as assessed by CEP17 CISH, was found in 19% of the @entity1 . Of these @entity1 , 60% also showed amplification of @entity2 measured by MLPA. However, none of the 111 @entity1 showed a true polysomy of chromosome 17 by MLPA. Only two @entity1 (1.8%) had a possible gain of 17q. Amplification of 17p was not found in any of the @entity1 , although a possible loss of 17p was found in one @entity1 . In conclusion, this extensive analysis of amplicons along chromosome 17 shows that true polysomy of chromosome 17, either of the whole chromosome or of the short or the long arm, is very rare in invasive @entity0 . Abnormal CEP17 copy numbers may therefore actually stem from high level gains or amplification of CEP17 regardless of copy number gains of the short and long arms of chromosome 17 and, at least in some cases, correction with CEP17 probes may provide misleading @entity2 gene status assessment results.

title: Absence of chromosome 17 polysomy in XXXX : analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.

answer: @entity0


abstract: PURPOSE: The results of @entity2 withdrawal in pancreas transplant recipients under @entity6 immunosuppression were analyzed. METHODS: From July 4, 1994 until April 30, 1998, 147 pancreas transplantations were performed in 141 @entity0 , including 126 simultaneous @entity1 . Baseline immunosuppression consisted of @entity6 and @entity3 without antilymphocyte induction. Twenty-three @entity0 were excluded from analysis because of early graft loss in 17 cases, retransplantation in 5 cases, and simultaneous pancreas-kidney transplantation after heart transplantation in 1 @entity0 . RESULTS: With a mean follow-up of 2.8+/-1.1 years (range 1.0 to 4.8 years), complete @entity2 withdrawal was achieved in 58 (47%) @entity0 with a mean time to @entity2 withdrawal of 15.2+/-8 months (range 4 to 40 months after transplantation). Of the entire cohort of 141 @entity0 , overall 1-, 2-, and 4-year @entity0 survival rates were 98%, 95.5%, and 86%, respectively. Overall 1-, 2-, and 4-year graft survival rates were 83%, 80%, and 71% (pancreas) and 95%, 91%, and 84% (kidney), respectively. Of the 124 @entity0 analyzed for @entity2 withdrawal, 1-, 2-, and 4-year @entity0 survival rates were 98%, 97%, and 92%, respectively. Overall 1-, 2-, and 4-year graft survival rates were 98%, 91.5%, 83% (pancreas) and 97%, 95%, and 91% (kidney). @entity0 , pancreas, and kidney survival rates at 1 year were 100%, 100%, and 98% (off @entity3 ) versus 97%, 91%, and 96% (on @entity3 , all NS) and at 4 years were 100%, 94%, and 95% (off @entity3 ) versus 78%, 68%, and 85% (on @entity3 , P = 0.01, 0.002, and NS, respectively). The cumulative risk of rejection at the time of follow-up was 76% for @entity0 on @entity3 versus 74% for @entity0 off @entity3 (P = NS). Seven @entity0 originally tapered off @entity3 were treated for subsequent rejection episodes, which were all @entity2 sensitive, and two of these seven @entity0 are currently off @entity3 . Thirteen patients received antilymphocyte therapy for @entity2 -resistant rejection, five of whom are now off @entity3 . @entity6 trough levels were 9.3+/-2.4 ng/ml (off @entity3 ) and 9.7+/-4.3 (on @entity3 , P = NS). Mean fasting @entity4 levels were 98+/-34 mg/dl (off @entity3 ) and 110+/-41 mg/dl (on @entity3 , P = NS). Mean glycosylated hemoglobin levels were 5.2+/-0.9% (off @entity3 ) and 6.2+/-2.1% (on @entity3 , P = 0.02), and mean serum @entity5 levels were 1.4+/-0.8 mg/dl (off @entity3 ) and 1.7+/-1.0 mg/dl (on @entity3 , P = 0.02). CONCLUSION: These data show for the first time that @entity2 withdrawal can be safely accomplished in pancreas transplant recipients maintained on @entity6 -based immunosuppression. @entity2 withdrawal is associated with excellent @entity0 and graft survival with no increase in the cumulative risk of rejection.

title: Results of pancreas transplantation after XXXX withdrawal under @entity6 immunosuppression.

answer: @entity2


abstract: PURPOSE: The results of @entity2 withdrawal in pancreas transplant recipients under @entity6 immunosuppression were analyzed. METHODS: From July 4, 1994 until April 30, 1998, 147 pancreas transplantations were performed in 141 @entity0 , including 126 simultaneous @entity1 . Baseline immunosuppression consisted of @entity6 and @entity3 without antilymphocyte induction. Twenty-three @entity0 were excluded from analysis because of early graft loss in 17 cases, retransplantation in 5 cases, and simultaneous pancreas-kidney transplantation after heart transplantation in 1 @entity0 . RESULTS: With a mean follow-up of 2.8+/-1.1 years (range 1.0 to 4.8 years), complete @entity2 withdrawal was achieved in 58 (47%) @entity0 with a mean time to @entity2 withdrawal of 15.2+/-8 months (range 4 to 40 months after transplantation). Of the entire cohort of 141 @entity0 , overall 1-, 2-, and 4-year @entity0 survival rates were 98%, 95.5%, and 86%, respectively. Overall 1-, 2-, and 4-year graft survival rates were 83%, 80%, and 71% (pancreas) and 95%, 91%, and 84% (kidney), respectively. Of the 124 @entity0 analyzed for @entity2 withdrawal, 1-, 2-, and 4-year @entity0 survival rates were 98%, 97%, and 92%, respectively. Overall 1-, 2-, and 4-year graft survival rates were 98%, 91.5%, 83% (pancreas) and 97%, 95%, and 91% (kidney). @entity0 , pancreas, and kidney survival rates at 1 year were 100%, 100%, and 98% (off @entity3 ) versus 97%, 91%, and 96% (on @entity3 , all NS) and at 4 years were 100%, 94%, and 95% (off @entity3 ) versus 78%, 68%, and 85% (on @entity3 , P = 0.01, 0.002, and NS, respectively). The cumulative risk of rejection at the time of follow-up was 76% for @entity0 on @entity3 versus 74% for @entity0 off @entity3 (P = NS). Seven @entity0 originally tapered off @entity3 were treated for subsequent rejection episodes, which were all @entity2 sensitive, and two of these seven @entity0 are currently off @entity3 . Thirteen patients received antilymphocyte therapy for @entity2 -resistant rejection, five of whom are now off @entity3 . @entity6 trough levels were 9.3+/-2.4 ng/ml (off @entity3 ) and 9.7+/-4.3 (on @entity3 , P = NS). Mean fasting @entity4 levels were 98+/-34 mg/dl (off @entity3 ) and 110+/-41 mg/dl (on @entity3 , P = NS). Mean glycosylated hemoglobin levels were 5.2+/-0.9% (off @entity3 ) and 6.2+/-2.1% (on @entity3 , P = 0.02), and mean serum @entity5 levels were 1.4+/-0.8 mg/dl (off @entity3 ) and 1.7+/-1.0 mg/dl (on @entity3 , P = 0.02). CONCLUSION: These data show for the first time that @entity2 withdrawal can be safely accomplished in pancreas transplant recipients maintained on @entity6 -based immunosuppression. @entity2 withdrawal is associated with excellent @entity0 and graft survival with no increase in the cumulative risk of rejection.

title: Results of pancreas transplantation after @entity2 withdrawal under XXXX immunosuppression.

answer: @entity6


abstract: 1. Under commercial and experimental conditions domestic @entity1 often cause @entity0 to pen-mates by repeated pecking, sometimes fatally. Environmental enrichment or lighting manipulations might be used to mitigate such injurious pecking. 2. This study examined responses to 4 treatments (2 rooms/treatment) of 8 groups of 100, non-beak trimmed, non-desnooded, male domestic @entity1 from 1 to 35 d of age. 3. Birds of 1 treatment were reared under conditions approximating to commercial rearing (12L:12D incandescent, Control) whereas the experimental treatments were 12L:12D incandescent plus supplemental ultraviolet radiation, straw supplementation of litter, pecking substrates and visual barriers (Enriched), 12L:12D fluorescent lighting (Fluorescent), and 2(2L:3D):2L:12D incandescent (Intermittent). 4. Compared to control birds, the incidence of @entity0 caused by wing or tail pecking were both lower in the Enriched but not significantly different in the Fluorescent or Intermittent. 5. Injuries caused by head pecking did not occur in the Enriched rooms but were observed in at least 1 of the rooms with Control, Fluorescent and Intermittent treatments. 6. Despite considerable environmental differences between treatments, there was remarkable consistency within each type of injurious pecking in age at which @entity0 were 1st recorded (wing pecking, 9.38+/-1.31 d; tail pecking, 20.43+/-2.42 d; head pecking, 27.8+/-2.13 d). The roles of feather emergence, hierarchy formation in @entity1 poults and appearance of feathers are discussed as possible explanations of these consistencies.

title: Effects of environmental enrichment, fluorescent and intermittent lighting on injurious pecking amongst male XXXX poults.

answer: @entity1


abstract: 1. TME, TMEn and metabolisability (TME/gross energy) of energy-yielding foodstuffs were determined in 1, 3 and 10 d old broiler chicks, using the assay method developed by Murakami et al. (1994), in order to characterise energy utilisation during the 10 d after hatching. 2. TME, TMEn and metabolisability of dextrin and starch were low in chicks aged 1 d, and increased with age up to 10 d. Energy values of @entity0 and maltose at days 1 and 3 could not be determined because of the @entity1 of birds soon after the feeding. TMEn and metabolisability of cereal sources were lower in d-old chicks than in those aged 3 and 10 d. At all ages, @entity4 was better utilised than @entity5 and @entity2 . 3. In the fat sources (coconut oil, beef tallow and safflower oil) no age dependency was observed in TME, TMEn and metabolisability. 4. Bioavailability of soyabean meal and fish meal was lower at 1 d than at 3 d and 10 d. Energy utilisation from casein was the highest among the protein sources tested and it was not age dependent. 5. It is concluded that energy utilisation of @entity3 and protein sources during 10 d post-hatch tended to increase with age. Among the energy yielding foodstuffs fat sources seem to be better utilised, with no age dependency.

title: Energy utilisation of XXXX , fat and protein sources in newly hatched broiler chicks.

answer: @entity3


abstract: The influence of @entity2 ( @entity3 ) on the proliferative activity of cells in different phases of cell cycle has been studied. @entity3 (5 mg/kg) was injected i.p. 3 days after the inoculation of 5 X 10(6) @entity4 cells, into F1 (DBA X C57 BL) @entity0 . It was shown that @entity3 causes degeneration of cells, being in G1- as well as in S-phase at the time of drug injection. Incorporation of @entity1 was suppressed for a period ranging from 2 to 12 hr after @entity3 administration, which is demonstrated by the decrease in the number of grains per cell. The number of cells labeled after 3H-TdR injection was also sharply decreased during this period. For a period of 3 until 15 hr after @entity3 administration the mitotic index decreased significantly as a result of inhibition of DNA synthesis. The blocking of the G1-S transition was evident during 4 hr after @entity3 . Thereafter the G1-S transition proceeds at a rate which is practically equal to that for nontreated controls. @entity3 did not inhibit transition to mitosis of cells being in G2-phase and in a very late S-phase at the time of drug injection. The sensitivity of G1-cells to the cytocidal effect of @entity3 shows that for @entity5 cells @entity3 can be classified as a cycle-specific drug killing both G1-and S-cells rather than S-phase specific agent with self-limitation.

title: Effect of XXXX on the cell cycle of @entity5 .

answer: @entity2


abstract: The influence of @entity2 ( @entity3 ) on the proliferative activity of cells in different phases of cell cycle has been studied. @entity3 (5 mg/kg) was injected i.p. 3 days after the inoculation of 5 X 10(6) @entity4 cells, into F1 (DBA X C57 BL) @entity0 . It was shown that @entity3 causes degeneration of cells, being in G1- as well as in S-phase at the time of drug injection. Incorporation of @entity1 was suppressed for a period ranging from 2 to 12 hr after @entity3 administration, which is demonstrated by the decrease in the number of grains per cell. The number of cells labeled after 3H-TdR injection was also sharply decreased during this period. For a period of 3 until 15 hr after @entity3 administration the mitotic index decreased significantly as a result of inhibition of DNA synthesis. The blocking of the G1-S transition was evident during 4 hr after @entity3 . Thereafter the G1-S transition proceeds at a rate which is practically equal to that for nontreated controls. @entity3 did not inhibit transition to mitosis of cells being in G2-phase and in a very late S-phase at the time of drug injection. The sensitivity of G1-cells to the cytocidal effect of @entity3 shows that for @entity5 cells @entity3 can be classified as a cycle-specific drug killing both G1-and S-cells rather than S-phase specific agent with self-limitation.

title: Effect of @entity2 on the cell cycle of XXXX .

answer: @entity5


abstract: Mutations in the @entity8 gene that codes for a forkhead transcription factor are associated with primary @entity7 that usually develops around puberty. @entity2 include @entity10 and, very frequently, superficial and deep @entity6 . Most mutations reported so far either truncate the protein or are missense mutations in the forkhead domain causing a loss of function. The haplo-insufficient state is associated with @entity3 in @entity1 as well as in @entity0 . We analyzed the @entity8 gene in 288 @entity0 with primary @entity7 and found 11 pathogenic mutations, of which 9 are novel. Of those, 5 were novel missense mutations of which 4 were located outside of the forkhead domain. To examine their pathogenic potential we performed a transactivation assay using a luciferase reporter construct driven by @entity9 response elements. We found that the mutations outside the forkhead domain cause a gain of function as measured by luciferase activity. @entity0 characteristics conform to previous reports with the exception of @entity10 , which was found in only 2 @entity0 out of 11. @entity8 mutations causing @entity10 reported thus far result in @entity4 and lead to @entity3 . Our results suggest that gain-of-function mutations may also cause @entity7 . One would expect that in this case, @entity5 would be the underlying abnormality. @entity0 with activating mutations might present with Meige disease.

title: Novel missense mutations in the XXXX gene alter transcriptional activity.

answer: @entity8


abstract: Higher omega-oxidation activities in the diabetic @entity0 and the starved one suggest that omega-oxidation mechanism plays an important role under these conditions. @entity12 that is the final product of omega-oxidation can be metabolized further by beta-oxidation, subsequently, formation of @entity13 and short-chain @entity12 might be increased in the liver. The physiological significance of omega-oxidation might consist in supplying the substrate of @entity6 cycle for utilization of @entity8 and excreting the short-chain @entity14 in urine resulting in the decrease of @entity7 bodies in the blood, especially in @entity1 and starvation. On the bases of these information, it is important to investigate the metabolism of @entity11 . Generally, @entity4 must be activated before they enter the metabolic pathway. By in vitro studies with @entity2 liver homogenate, we have recently demonstrated that octadecaned-ioic acid must be activated by @entity3 -Mg2+ and @entity10 as @entity15 is. However, it has not been studied to compare the activity of @entity9 synthetase on mono and @entity12 . So, in this report, we assayed the activity of @entity9 synthetase in beef liver preparations using palmitic or @entity16 (C1;16) as substrate. The results are as follows 1) Activation capacity of the supernatant of sonicated mitochondria was less than that of sonicated microsome for either @entity5 or hexadecanedioate. 2) Activation capacity for hexadecanedioate was less than that for @entity5 in both supernatant of sonicated mitochondria and that of sonicated microsome. 3) In our experiment, it might be suggested that the subcellular distribution of hexadecanedioate activation is almost identical with that of @entity5 activation.

title: [ XXXX synthetase activity of long-chain mono and @entity12 in beef liver preparations (author's transl)].

answer: @entity9


abstract: Higher omega-oxidation activities in the diabetic @entity0 and the starved one suggest that omega-oxidation mechanism plays an important role under these conditions. @entity12 that is the final product of omega-oxidation can be metabolized further by beta-oxidation, subsequently, formation of @entity13 and short-chain @entity12 might be increased in the liver. The physiological significance of omega-oxidation might consist in supplying the substrate of @entity6 cycle for utilization of @entity8 and excreting the short-chain @entity14 in urine resulting in the decrease of @entity7 bodies in the blood, especially in @entity1 and starvation. On the bases of these information, it is important to investigate the metabolism of @entity11 . Generally, @entity4 must be activated before they enter the metabolic pathway. By in vitro studies with @entity2 liver homogenate, we have recently demonstrated that octadecaned-ioic acid must be activated by @entity3 -Mg2+ and @entity10 as @entity15 is. However, it has not been studied to compare the activity of @entity9 synthetase on mono and @entity12 . So, in this report, we assayed the activity of @entity9 synthetase in beef liver preparations using palmitic or @entity16 (C1;16) as substrate. The results are as follows 1) Activation capacity of the supernatant of sonicated mitochondria was less than that of sonicated microsome for either @entity5 or hexadecanedioate. 2) Activation capacity for hexadecanedioate was less than that for @entity5 in both supernatant of sonicated mitochondria and that of sonicated microsome. 3) In our experiment, it might be suggested that the subcellular distribution of hexadecanedioate activation is almost identical with that of @entity5 activation.

title: [ @entity9 synthetase activity of long-chain mono and XXXX in beef liver preparations (author's transl)].

answer: @entity12


abstract: BACKGROUND/AIMS: The aim of the present article was to compare stapled haemorrhoidectomy, and haemorrhoidal artery ligation with open haemorrhoidectomy with respect to the @entity4 , symptom control, and manometric alterations. METHODOLOGY: Forty five @entity0 with third or fourth-degree haemorrhoids were randomly classified into three groups; first group managed by stapled haemorrhoidectomy, second group managed by conventional haemorrhoidectomy and third group managed by Doppler guided haemorrhoidal artery ligation. (15 @entity0 each) Preoperative and 12 weeks postoperative anorectal manometry were done for all @entity0 . RESULTS: There was a significant difference of the operative time between stapled group and Milligan-Morgan group (p < 0.001) while no significant difference between stapled group and Doppler group. The @entity2 scores were significantly higher in open group (p < 0.001) during the first 24 hours at the time of first motion and one week after operation. Postoperative control of prolapsed symptoms was significantly better with open diathermy haemorrhoidectomy than with stapled. The control of other symptoms was similar with regard to @entity6 , @entity2 , @entity1 , and @entity5 scores. Anorectal manometry showed a decrease in the maximum resting pressure and maximum squeeze pressure in all groups, but this decrease was only significant in the stapled haemorrhoidectomy group. CONCLUSIONS: Stapled and Doppler haemorrhoidectomy is as effective as conventional haemorrhoidectomy for the treatment of haemorrhoids, but with the exception of @entity3 . There is a need for long-term follow-up for the changes in manometric parameters after haemorrhoidectomy.

title: Conventional haemorrhoidectomy, stapled haemorrhoidectomy, Doppler guided haemorrhoidectomy artery ligation; post operative XXXX and anorectal manometric assessment.

answer: @entity2


abstract: BACKGROUND: An increasing number of reports indicate symptomatic relief of @entity2 after cholecystectomy for @entity3 . Despite this, cholecystectomy as a treatment for @entity3 remains controversial. Our aim was to determine efficacy of cholecystectomy in alleviating @entity3 symptoms and the correlation with histologic findings. METHODS: Records of @entity0 with gallbladder ejection fraction <35% between January 1994 and February 1999 were reviewed. Gallbladder pathology and degree of symptomatic improvement were determined on follow-up. RESULTS: Of the 27 cholecystectomy @entity0 , 24 (89%) had significant improvement, 2 (7%) had partial improvement, and 1 (4%) had minimal improvement. Ten @entity0 (43%) had normal gall-bladder, and 9 (90%) of them had significant improvement after cholecystectomy. Of the 6 nonsurgical @entity0 , none had significant improvement, 4 (67%) had partial improvement, and 2 (33%) had minimal improvement. CONCLUSIONS: @entity3 @entity0 who underwent cholecystectomy had significantly greater symptom improvement compared with nonsurgical @entity0 . Pathologic correlation suggests @entity1 may not be the only cause of @entity4 . Cholecystectomy should be a first-line therapy for @entity3 @entity0 .

title: Cholecystectomy is an effective treatment for XXXX .

answer: @entity3


abstract: BACKGROUND/AIMS: Adhesions following intraperitoneal surgery are frequent causes of @entity4 . Attempts to prevent @entity2 have mostly proven disappointing clinically. Currently used by ophthalmologists in ocular surface disorders, amniotic membrane transplantation can reduce @entity0 and promote re-epithelization. We used amniotic membrane for facilitating peritoneal regeneration and prevention of adhesions with surgical @entity3 . METHODOLOGY: 20 @entity1 were randomized in equal number into treatment or control groups. Seven days after operation, the incidence and severity of adhesions were evaluated. Histologic and immunohistochemical analyses were examined at 1, 4, 10 weeks after operation. RESULTS: While severe adhesions were observed after 1 week between the cecum and surrounding organs in the control group, adhesion formation was significantly reduced in the amniotic membrane group. Histologic examination demonstrated that free-floating myofibroblasts in the peritoneal cavity attached to surfaces of amniotic membrane grafts to form a layered structure. Free-floating mesothelial cells were incorporated into the regenerating mesothelium on the myofibroblast layer in 4 weeks, while implanted amniotic membrane grafts were absorbed by 10 weeks. In the amniotic membrane group the cecum appeared nearly normal. CONCLUSIONS: Amniotic membrane grafts reduced intraperitoneal adhesions after surgical @entity3 , were well absorbed, and served as a substrate for regenerating mesothelium.

title: Regeneration of peritoneum using amniotic membrane to prevent XXXX .

answer: @entity2


abstract: BACKGROUND/AIMS: The purpose of this study was to examine the roles of @entity1 @entity2 factor-alpha ( @entity5 ), @entity6 , @entity8 , and @entity4 ( @entity4 ) in @entity0 with @entity7 ( @entity7 ) and @entity3 ( @entity3 ). METHODOLOGY: @entity4 and cytokine serum concentrations were determined via EIA or ELISA. RESULTS: In total, 81 @entity0 were included, including 9 healthy controls, 36 @entity7 @entity0 , and 36 @entity3 @entity0 . Significant differences in @entity4 , @entity5 , @entity6 , and @entity8 between the three groups were noted (p < 0.001). @entity4 was lowest in the healthy subjects, intermediate in @entity7 @entity0 and highest in @entity3 @entity0 (all p < 0.001). 11-6 and 11-18 concentrations were significantly higher in the @entity3 group than the other two groups. @entity3 and @entity7 @entity0 with @entity4 concentration > 7ng/ml had increased @entity8 concentrations compared to both the other groups p < 0.001). In contrast to previously published studies, @entity5 was highest in the healthy group, intermediate in the @entity3 group, and lowest in the @entity7 group (p < 0.001). CONCLUSIONS: @entity8 may be a potential @entity1 marker in combination with @entity6 and @entity4 in the diagnosis of @entity3 , but further research including a larger population of @entity0 is essential. Further research is warranted.

title: Cytokine evaluation in XXXX and @entity3 .

answer: @entity7


abstract: BACKGROUND/AIMS: The purpose of this study was to examine the roles of @entity1 @entity2 factor-alpha ( @entity5 ), @entity6 , @entity8 , and @entity4 ( @entity4 ) in @entity0 with @entity7 ( @entity7 ) and @entity3 ( @entity3 ). METHODOLOGY: @entity4 and cytokine serum concentrations were determined via EIA or ELISA. RESULTS: In total, 81 @entity0 were included, including 9 healthy controls, 36 @entity7 @entity0 , and 36 @entity3 @entity0 . Significant differences in @entity4 , @entity5 , @entity6 , and @entity8 between the three groups were noted (p < 0.001). @entity4 was lowest in the healthy subjects, intermediate in @entity7 @entity0 and highest in @entity3 @entity0 (all p < 0.001). 11-6 and 11-18 concentrations were significantly higher in the @entity3 group than the other two groups. @entity3 and @entity7 @entity0 with @entity4 concentration > 7ng/ml had increased @entity8 concentrations compared to both the other groups p < 0.001). In contrast to previously published studies, @entity5 was highest in the healthy group, intermediate in the @entity3 group, and lowest in the @entity7 group (p < 0.001). CONCLUSIONS: @entity8 may be a potential @entity1 marker in combination with @entity6 and @entity4 in the diagnosis of @entity3 , but further research including a larger population of @entity0 is essential. Further research is warranted.

title: Cytokine evaluation in @entity7 and XXXX .

answer: @entity3


abstract: BACKGROUND/AIMS: A retrospective evaluation was oerformed to determine whether the intensity of @entity3 , @entity7 or @entity5 expression predicts response to preoperative chemoradiotherapy in locally advanced @entity2 . METHODOLOGY: Thirty-six @entity0 ( @entity8 or N+) were studied. Preoperative treatment consisted of 30-45Gy of radiation with continuous @entity6 and weekly @entity4 . Expression of @entity3 , @entity7 and @entity5 in pretreatment biopsies was assessed by immunohistochemistry. Level of expression was determined from the intensity and extent of staining. @entity1 downstaging was defined as a reduction of at least one T-stage level and/or finding of intense @entity1 regression in histopathologic examination. RESULTS: Seventeen @entity0 responded to chemoradiation: 8 @entity0 had pathologic complete response, 9 @entity0 were downstaged. The multivariate analysis showed no significant influence of @entity3 (p = 0.76), @entity7 (p = 0.10) nor @entity5 (p = 0.70) expression upon @entity1 response. Response was found in 52% of @entity0 with low, and in 40% of @entity0 with high @entity3 staining (p = 0.21); in 54% of @entity0 with low, and in 30% of @entity0 with high @entity7 staining (p = 0.14); and in 48% of @entity0 with low, and in 43% of @entity0 with high @entity5 staining (p = 0.32). CONCLUSIONS: We found no significant influence of @entity3 , @entity7 nor @entity5 expression upon response to preoperative chemoradiotherapy in @entity2 .

title: Expression of @entity3 , @entity7 and XXXX does not correlate with response to preoperative @entity2 .

answer: @entity5


abstract: BACKGROUND/AIMS: A retrospective evaluation was oerformed to determine whether the intensity of @entity3 , @entity7 or @entity5 expression predicts response to preoperative chemoradiotherapy in locally advanced @entity2 . METHODOLOGY: Thirty-six @entity0 ( @entity8 or N+) were studied. Preoperative treatment consisted of 30-45Gy of radiation with continuous @entity6 and weekly @entity4 . Expression of @entity3 , @entity7 and @entity5 in pretreatment biopsies was assessed by immunohistochemistry. Level of expression was determined from the intensity and extent of staining. @entity1 downstaging was defined as a reduction of at least one T-stage level and/or finding of intense @entity1 regression in histopathologic examination. RESULTS: Seventeen @entity0 responded to chemoradiation: 8 @entity0 had pathologic complete response, 9 @entity0 were downstaged. The multivariate analysis showed no significant influence of @entity3 (p = 0.76), @entity7 (p = 0.10) nor @entity5 (p = 0.70) expression upon @entity1 response. Response was found in 52% of @entity0 with low, and in 40% of @entity0 with high @entity3 staining (p = 0.21); in 54% of @entity0 with low, and in 30% of @entity0 with high @entity7 staining (p = 0.14); and in 48% of @entity0 with low, and in 43% of @entity0 with high @entity5 staining (p = 0.32). CONCLUSIONS: We found no significant influence of @entity3 , @entity7 nor @entity5 expression upon response to preoperative chemoradiotherapy in @entity2 .

title: Expression of XXXX , @entity7 and @entity5 does not correlate with response to preoperative @entity2 .

answer: @entity3


abstract: BACKGROUND/AIMS: A retrospective evaluation was oerformed to determine whether the intensity of @entity3 , @entity7 or @entity5 expression predicts response to preoperative chemoradiotherapy in locally advanced @entity2 . METHODOLOGY: Thirty-six @entity0 ( @entity8 or N+) were studied. Preoperative treatment consisted of 30-45Gy of radiation with continuous @entity6 and weekly @entity4 . Expression of @entity3 , @entity7 and @entity5 in pretreatment biopsies was assessed by immunohistochemistry. Level of expression was determined from the intensity and extent of staining. @entity1 downstaging was defined as a reduction of at least one T-stage level and/or finding of intense @entity1 regression in histopathologic examination. RESULTS: Seventeen @entity0 responded to chemoradiation: 8 @entity0 had pathologic complete response, 9 @entity0 were downstaged. The multivariate analysis showed no significant influence of @entity3 (p = 0.76), @entity7 (p = 0.10) nor @entity5 (p = 0.70) expression upon @entity1 response. Response was found in 52% of @entity0 with low, and in 40% of @entity0 with high @entity3 staining (p = 0.21); in 54% of @entity0 with low, and in 30% of @entity0 with high @entity7 staining (p = 0.14); and in 48% of @entity0 with low, and in 43% of @entity0 with high @entity5 staining (p = 0.32). CONCLUSIONS: We found no significant influence of @entity3 , @entity7 nor @entity5 expression upon response to preoperative chemoradiotherapy in @entity2 .

title: Expression of @entity3 , @entity7 and @entity5 does not correlate with response to preoperative XXXX .

answer: @entity2


abstract: BACKGROUND/AIMS: A retrospective evaluation was oerformed to determine whether the intensity of @entity3 , @entity7 or @entity5 expression predicts response to preoperative chemoradiotherapy in locally advanced @entity2 . METHODOLOGY: Thirty-six @entity0 ( @entity8 or N+) were studied. Preoperative treatment consisted of 30-45Gy of radiation with continuous @entity6 and weekly @entity4 . Expression of @entity3 , @entity7 and @entity5 in pretreatment biopsies was assessed by immunohistochemistry. Level of expression was determined from the intensity and extent of staining. @entity1 downstaging was defined as a reduction of at least one T-stage level and/or finding of intense @entity1 regression in histopathologic examination. RESULTS: Seventeen @entity0 responded to chemoradiation: 8 @entity0 had pathologic complete response, 9 @entity0 were downstaged. The multivariate analysis showed no significant influence of @entity3 (p = 0.76), @entity7 (p = 0.10) nor @entity5 (p = 0.70) expression upon @entity1 response. Response was found in 52% of @entity0 with low, and in 40% of @entity0 with high @entity3 staining (p = 0.21); in 54% of @entity0 with low, and in 30% of @entity0 with high @entity7 staining (p = 0.14); and in 48% of @entity0 with low, and in 43% of @entity0 with high @entity5 staining (p = 0.32). CONCLUSIONS: We found no significant influence of @entity3 , @entity7 nor @entity5 expression upon response to preoperative chemoradiotherapy in @entity2 .

title: Expression of @entity3 , XXXX and @entity5 does not correlate with response to preoperative @entity2 .

answer: @entity7


abstract: BACKGROUND/AIM: Compared with conventional pharmacological therapies, bariatric surgery has been shown to cause greater and- sustained @entity2 . It was aimed to evaluate @entity2 in @entity1 @entity0 after laparoscopic adjustable gastric banding surgery using information typically available during the initial evaluation studied before bariatric surgery and genes. METHODOLOGY: 74 @entity0 undergoing laparoscopic adjustable gastric banding (LAGB) were enrolled. Artificial Neural Network technology was used to predict @entity2 . RESULTS: We studied 74 @entity0 consisting of 22 @entity0 and 52 @entity0 2 years after operation. Mean age was 31.7 +/- 9.1 years. 27 (36.5%) @entity0 had successful @entity2 (excess @entity2 >50%) while 47 (63.5%) did not. ANN provided predicted factors on gender, @entity4 , @entity3 and two genes: re4684846_r, @entity5 _r which were associated with success. CONCLUSION: Artificial neural network is a better modeling technique and the predictive accuracy is higher on the basis of multiple variables related to laboratory tests. Our finding gave demonstrated result that @entity1 @entity0 of successful @entity2 after laparoscopic adjustable gastric banding surgery were @entity0 , having little lower @entity4 and @entity3 , and carrying GG genotype on @entity6 and with at least one T allele on @entity5 . In these cases, @entity2 will give better results.

title: Prediction of successful XXXX after laparoscopic adjustable gastric banding.

answer: @entity2


abstract: OBJECTIVE: To observe the therapeutic effect of ear-electroacupuncture (Ear-EA) on @entity4 in @entity0 with @entity1 and to explore its underlying mechanism. METHODS: A total of 80 @entity1 @entity0 were randomly and equally divided into ear-EA group and body-EA group. EA (50 Hz, 0.5-0.8 mA) was applied to auricular points (Uterus, Subcortex, Shenmen, Endocrine, etc.) and body acupoints [Tianshu (ST 25), Qihai (CV 6), Guanyuan (CV 4), Sanyinjiao ( @entity6 ), Diji ( @entity8 ), Uterus (EX-CA 1), etc.] respectively for 30 min, once every other day for 3 months. @entity4 severity score (DSS) was assessed and plasma @entity5 ( @entity3 ) and @entity7 levels detected by radioimmunoassay. RESULTS: Compared with pre-treatment, DSS lowered significantly during the 1st and 2nd menstrual cycle in body-EA group, and during the 1st, 2nd and 3rd menstruation in ear-EA group; and the DSS of ear-EA group during the 3rd menstruation was evidently lower than that of body-EA group (P < 0.05). During the 3rd menstrual onset after the treatment, plasma @entity3 contents in both groups decreased obviously (P < 0.01), and plasma @entity7 , levels increased considerably in comparison with pre-treatment (P < 0.01). Comparison between two groups during the 3rd menstruation showed that plasma @entity3 level of ear-EA group was markedly lower than that of body-EA group, and @entity7 , level of ear-EA group was significantly higher than that of body-EA group (P < 0.05). No significant difference was found between two groups in clinical therapeutic effect (P > 0.05). CONCLUSION: Both ear-EA and body-EA can effectively relieve @entity1 -induced @entity4 , and the former is superior to the later in reducing @entity2 severity, which may be closely related to their effects in reducing plasma @entity3 and raising @entity7 level.

title: [Randomized controlled study on ear-electroacupuncture treatment of @entity1 -induced XXXX in @entity0 ].

answer: @entity4


abstract: OBJECTIVE: To observe the therapeutic effect of ear-electroacupuncture (Ear-EA) on @entity4 in @entity0 with @entity1 and to explore its underlying mechanism. METHODS: A total of 80 @entity1 @entity0 were randomly and equally divided into ear-EA group and body-EA group. EA (50 Hz, 0.5-0.8 mA) was applied to auricular points (Uterus, Subcortex, Shenmen, Endocrine, etc.) and body acupoints [Tianshu (ST 25), Qihai (CV 6), Guanyuan (CV 4), Sanyinjiao ( @entity6 ), Diji ( @entity8 ), Uterus (EX-CA 1), etc.] respectively for 30 min, once every other day for 3 months. @entity4 severity score (DSS) was assessed and plasma @entity5 ( @entity3 ) and @entity7 levels detected by radioimmunoassay. RESULTS: Compared with pre-treatment, DSS lowered significantly during the 1st and 2nd menstrual cycle in body-EA group, and during the 1st, 2nd and 3rd menstruation in ear-EA group; and the DSS of ear-EA group during the 3rd menstruation was evidently lower than that of body-EA group (P < 0.05). During the 3rd menstrual onset after the treatment, plasma @entity3 contents in both groups decreased obviously (P < 0.01), and plasma @entity7 , levels increased considerably in comparison with pre-treatment (P < 0.01). Comparison between two groups during the 3rd menstruation showed that plasma @entity3 level of ear-EA group was markedly lower than that of body-EA group, and @entity7 , level of ear-EA group was significantly higher than that of body-EA group (P < 0.05). No significant difference was found between two groups in clinical therapeutic effect (P > 0.05). CONCLUSION: Both ear-EA and body-EA can effectively relieve @entity1 -induced @entity4 , and the former is superior to the later in reducing @entity2 severity, which may be closely related to their effects in reducing plasma @entity3 and raising @entity7 level.

title: [Randomized controlled study on ear-electroacupuncture treatment of XXXX -induced @entity4 in @entity0 ].

answer: @entity1


abstract: OBJECTIVE: To observe the therapeutic effect of ear-electroacupuncture (Ear-EA) on @entity4 in @entity0 with @entity1 and to explore its underlying mechanism. METHODS: A total of 80 @entity1 @entity0 were randomly and equally divided into ear-EA group and body-EA group. EA (50 Hz, 0.5-0.8 mA) was applied to auricular points (Uterus, Subcortex, Shenmen, Endocrine, etc.) and body acupoints [Tianshu (ST 25), Qihai (CV 6), Guanyuan (CV 4), Sanyinjiao ( @entity6 ), Diji ( @entity8 ), Uterus (EX-CA 1), etc.] respectively for 30 min, once every other day for 3 months. @entity4 severity score (DSS) was assessed and plasma @entity5 ( @entity3 ) and @entity7 levels detected by radioimmunoassay. RESULTS: Compared with pre-treatment, DSS lowered significantly during the 1st and 2nd menstrual cycle in body-EA group, and during the 1st, 2nd and 3rd menstruation in ear-EA group; and the DSS of ear-EA group during the 3rd menstruation was evidently lower than that of body-EA group (P < 0.05). During the 3rd menstrual onset after the treatment, plasma @entity3 contents in both groups decreased obviously (P < 0.01), and plasma @entity7 , levels increased considerably in comparison with pre-treatment (P < 0.01). Comparison between two groups during the 3rd menstruation showed that plasma @entity3 level of ear-EA group was markedly lower than that of body-EA group, and @entity7 , level of ear-EA group was significantly higher than that of body-EA group (P < 0.05). No significant difference was found between two groups in clinical therapeutic effect (P > 0.05). CONCLUSION: Both ear-EA and body-EA can effectively relieve @entity1 -induced @entity4 , and the former is superior to the later in reducing @entity2 severity, which may be closely related to their effects in reducing plasma @entity3 and raising @entity7 level.

title: [Randomized controlled study on ear-electroacupuncture treatment of @entity1 -induced @entity4 in XXXX ].

answer: @entity0


abstract: Purpose. This paper aims at describing the combined penoscrotal and perineal approach for placement of penile prosthesis in cases of severe corporal @entity1 and @entity2 . Materials and methods. Three @entity0 with extensive corporal @entity1 underwent penile prosthesis placement via combined penoscrotal and perineal approach from 1997 to 2006. Follow-up ranged from 15 to 129 months. Results. All @entity0 underwent successful implantation of semirigid penile prosthesis. There were no short- or long-term complications. Conclusions. Results on combined penoscrotal and perineal approach to penile prosthetic surgery in this preliminary series of @entity0 suggest that it is a safe technique and increases the chance of successful outcome in the surgical management of severe corporal @entity1 .

title: A preliminary report on combined penoscrotal and perineal approach for placement of penile prosthesis with corporal XXXX .

answer: @entity1


abstract: @entity1 (SNC) in @entity0 were produced by electrolytic coagulation or by an injection of @entity10 . Two to 5 weeks later, after being preselected for @entity14 -induced @entity3 behavior, the animals were administered narcotic agonists or antagonists and their circling behavior was observed. @entity5 , @entity2 , @entity16 , @entity17 or @entity15 induced @entity3 movements; both @entity6 and @entity13 were without effect. Ipsilateral circling was also observed in @entity0 with unilateral electrolytic lesions after administration of agents that are thought to enhance central dopaminergic activities: @entity9 , @entity11 and @entity12 . In @entity0 with unilateral electrolytic or @entity10 SNC lesions that were rendered highly @entity5 -dependent by multiple- @entity5 pellet implantation, contralateral (C) circling behavior was observed within 1 to 2 minutes after a @entity6 challenge; the onset and duration of C circling behavior coincided with the initial appearance and duration of precipitated- @entity5 withdrawal signs. C circling was also observed after administration of putative @entity4 receptor blockers, @entity8 and @entity7 in @entity0 with either unilateral electrolytic or @entity10 SNC lesions. @entity5 pretreatment diminished both the C circling intensity and the appearance of withdrawal signs observed after a @entity6 challenge in @entity5 -dependent, SNC-lesioned @entity0 . The @entity6 -precipitated withdrawal in unilaterally lesioned @entity5 -dependent @entity0 was accompanied by a 20% elevation of neostriatal @entity4 in the intact side. In contrast to the effects of a chronic @entity1 in decreasing neostriatal @entity4 , a 77% increase was observed in the lesioned side 30 minutes after electrolytic coagulation. Thus, narcotic agonists and partial agonists may enhance central dopaminergic activities and @entity6 -precipitated withdrawal may involve a diminution in central dopaminergic activities of the nigroneostriatal pathway.

title: Circling behavior after narcotic drugs and during XXXX -precipitated abstinence in @entity0 with unilateral nigral lesions.

answer: @entity6